Financial Contrast: OrthoPediatrics (NASDAQ:KIDS) versus IceCure Medical (NASDAQ:ICCM)

OrthoPediatrics (NASDAQ:KIDS) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Earnings & Valuation

This table compares OrthoPediatrics and IceCure Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$148.73 million	4.18	-$20.97 million	($1.09)	-23.57
IceCure Medical	$3.23 million	8.76	-$14.65 million	($0.30)	-2.07

IceCure Medical has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OrthoPediatrics and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-14.35%	-5.44%	-4.67%
IceCure Medical	-410.22%	-111.27%	-81.41%

Volatility & Risk

OrthoPediatrics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500.

Institutional & Insider Ownership

69.1% of OrthoPediatrics shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 31.8% of OrthoPediatrics shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for OrthoPediatrics and IceCure Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	0	1	2	0	2.67
IceCure Medical	0	0	2	0	3.00

OrthoPediatrics presently has a consensus target price of $40.00, suggesting a potential upside of 55.70%. IceCure Medical has a consensus target price of $2.70, suggesting a potential upside of 335.48%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than OrthoPediatrics.

Summary

OrthoPediatrics beats IceCure Medical on 7 of the 12 factors compared between the two stocks.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.